• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新加坡Vogt-小柳-原田病的预后因素

Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore.

作者信息

Chee Soon-Phaik, Jap Aliza, Bacsal Kristine

机构信息

Singapore National Eye Centre, Singapore.

出版信息

Am J Ophthalmol. 2009 Jan;147(1):154-161.e1. doi: 10.1016/j.ajo.2008.07.044. Epub 2008 Oct 2.

DOI:10.1016/j.ajo.2008.07.044
PMID:18834575
Abstract

PURPOSE

To determine prognostic factors of Vogt-Koyanagi-Harada disease (VKH).

DESIGN

Retrospective noninterventional.

METHODS

Chart review of VKH patients of Singapore National Eye Centre for age at onset (age), gender, race, presenting visual acuity (VA) and VA at one month after starting treatment, severity of inflammation, treatment regime, and hearing loss. Outcome measures were: VA, persistent inflammation, cataracts, glaucoma, macular lesions, chorioretinal degeneration, and vitiligo at three years after onset.

RESULTS

There were 134 eyes of 67 patients. Majority were Chinese (n = 53, 79.1%) and female (n = 40, 59.7%). Median duration of follow-up was 9.1 years (range, 3.0 to 53.6 years). Median age was 42.3 years (range, 5.4 to 70.9 years). Main prognostic factors were VA at one month, age, and treatment regime. Good VA at one month was associated with greater likelihood of good VA at three years (odds ratio [OR], 43.9; P = .02), less persistent inflammation (OR, 0.5; P = .006), cataract (OR, 0.10; P = .01), and chorioretinal degeneration (OR, 0.2; P = .04). Older age was associated with higher likelihood of cataract (OR, 1.1; P = .02), chorioretinal degeneration (OR, 1.1; P = .03), and vitiligo (OR, 1.1; P = .004). Early treatment with high-dose systemic corticosteroids resulted in less persistent inflammation (OR, 0.2; P = .04). Late high corticosteroid treatment was associated with greater risk of cataract (OR, 9.6; P = .03).

CONCLUSION

Good VA at one month, younger age at onset, and early treatment with high-dose corticosteroids were associated with better outcomes.

摘要

目的

确定伏格特-小柳-原田病(VKH)的预后因素。

设计

回顾性非干预性研究。

方法

对新加坡国家眼科中心的VKH患者病历进行回顾,内容包括发病年龄、性别、种族、初诊视力及开始治疗后1个月时的视力、炎症严重程度、治疗方案和听力损失情况。观察指标为发病3年后的视力、持续性炎症、白内障、青光眼、黄斑病变、脉络膜视网膜变性和白癜风。

结果

共67例患者的134只眼。大多数为华裔(n = 53,79.1%),女性居多(n = 40,59.7%)。中位随访时间为9.1年(范围3.0至53.6年)。中位年龄为42.3岁(范围5.4至70.9岁)。主要预后因素为1个月时的视力、年龄和治疗方案。1个月时视力良好与3年后视力良好的可能性更大相关(优势比[OR],43.9;P = 0.02),持续性炎症较少(OR,0.5;P = 0.006),白内障发病率较低(OR,0.10;P = 0.01),脉络膜视网膜变性发病率较低(OR,0.2;P = 0.04)。年龄较大与白内障(OR,1.1;P = 0.02)、脉络膜视网膜变性(OR,1.1;P = 0.03)和白癜风(OR,1.1;P = 0.004)的发病可能性较高相关。早期使用高剂量全身糖皮质激素治疗可减少持续性炎症(OR,0.2;P = 0.04)。晚期大剂量糖皮质激素治疗与白内障风险增加相关(OR,9.6;P = 0.03)。

结论

1个月时视力良好、发病年龄较小以及早期使用高剂量糖皮质激素治疗与更好的预后相关。

相似文献

1
Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore.新加坡Vogt-小柳-原田病的预后因素
Am J Ophthalmol. 2009 Jan;147(1):154-161.e1. doi: 10.1016/j.ajo.2008.07.044. Epub 2008 Oct 2.
2
Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease.初始口服皮质类固醇治疗持续时间对 Vogt-小柳原田病炎症复发的影响。
Eye (Lond). 2009 Mar;23(3):543-8. doi: 10.1038/eye.2008.89. Epub 2008 Mar 28.
3
Vogt-Koyanagi-Harada disease in children.儿童伏格特-小柳-原田病
Eye (Lond). 2008 Sep;22(9):1124-31. doi: 10.1038/sj.eye.6702859. Epub 2007 May 4.
4
Vogt-Koyanagi-Harada disease in Thai patients.泰国患者的伏格特-小柳-原田病
J Med Assoc Thai. 2005 Nov;88 Suppl 9:S26-30.
5
Risk factors for poor visual outcome following cataract surgery in Vogt-Koyanagi-Harada disease.Vogt-Koyanagi-Harada 病患者白内障手术后视力预后不良的危险因素。
Br J Ophthalmol. 2011 Nov;95(11):1542-6. doi: 10.1136/bjo.2010.184796. Epub 2011 Feb 24.
6
Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.评估急性Vogt-小柳-原田病中糖皮质激素给药途径对预后的影响。
Am J Ophthalmol. 2006 Jul;142(1):119-24. doi: 10.1016/j.ajo.2006.02.049.
7
Vogt-Koyanagi-Harada disease: clinical outcomes.伏格特-小柳-原田病:临床结局
Am J Ophthalmol. 2005 Oct;140(4):674-8. doi: 10.1016/j.ajo.2005.04.052.
8
Correlation between sunset glow fundus and initial dosage of corticosteroid in patients with Vogt-Koyanagi-Harada disease.伏格特-小柳-原田病患者晚霞样眼底与糖皮质激素初始剂量的相关性
Am J Ophthalmol. 2009 May;147(5):946; author reply 946-7. doi: 10.1016/j.ajo.2009.02.005.
9
The outcomes of indocyanine green angiography monitored immunotherapy in Vogt-Koyanagi-Harada disease.吲哚菁绿血管造影监测免疫治疗 Vogt-小柳原田病的结果。
Br J Ophthalmol. 2013 Feb;97(2):130-3. doi: 10.1136/bjophthalmol-2012-302538. Epub 2012 Dec 4.
10
Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease.伏格特-小柳-原田病前段复发时并发脉络膜炎症。
Am J Ophthalmol. 2008 Mar;145(3):480-486. doi: 10.1016/j.ajo.2007.10.012. Epub 2008 Jan 11.

引用本文的文献

1
A Case of Vogt-Koyanagi-Harada Disease: Diagnosis Based on the Presence of Vitiligo and Sunset Glow Fundus Without Ocular Symptoms.一例Vogt-小柳-原田病:基于白癜风和晚霞样眼底表现且无眼部症状进行诊断
Cureus. 2025 Jan 29;17(1):e78209. doi: 10.7759/cureus.78209. eCollection 2025 Jan.
2
Early Changes in Ocular Biomarkers in Patients with Vogt-Koyanagi-Harada Disease after Pulse Steroid Therapy.伏格特-小柳-原田病患者脉冲类固醇治疗后眼部生物标志物的早期变化
Ophthalmologica. 2025;248(1):40-53. doi: 10.1159/000542724. Epub 2024 Nov 21.
3
Vogt-Koyanagi-Harada Disease and COVID.
伏格特-小柳-原田病与新冠病毒
J Clin Med. 2023 Sep 27;12(19):6242. doi: 10.3390/jcm12196242.
4
[Recurrent chronic Vogt-Koyanagi-Harada syndrome or sarcoidosis? A Gloomy diagnosis].[复发性慢性葡萄膜大脑炎综合征还是结节病?一个令人沮丧的诊断]
Rev Med Inst Mex Seguro Soc. 2023 Sep 4;61(5):702-706. doi: 10.5281/zenodo.8316491.
5
A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease.一项免疫抑制剂与生物制剂治疗 Vogt-Koyanagi-Harada 病的随机非劣效性试验。
Nat Commun. 2023 Jun 24;14(1):3768. doi: 10.1038/s41467-023-39483-5.
6
Acute phase clinical manifestations of patients with Vogt-Koyanagi-Harada disease in Southern China.中国南方 Vogt-Koyanagi-Harada 病患者的急性期临床表现。
BMC Ophthalmol. 2023 May 5;23(1):199. doi: 10.1186/s12886-023-02952-y.
7
Chromatin accessibility analysis reveals regulatory dynamics and therapeutic relevance of Vogt-Koyanagi-Harada disease.染色质可及性分析揭示了 Vogt-Koyanagi-Harada 病的调控动态和治疗相关性。
Commun Biol. 2022 May 26;5(1):506. doi: 10.1038/s42003-022-03430-9.
8
Mucosal-associated invariant T cells have therapeutic potential against ocular autoimmunity.黏膜相关恒定 T 细胞具有治疗眼自身免疫性疾病的潜力。
Mucosal Immunol. 2022 Feb;15(2):351-361. doi: 10.1038/s41385-021-00469-5. Epub 2021 Nov 13.
9
Classification Criteria for Vogt-Koyanagi-Harada Disease.Vogt-Koyanagi-Harada 病的分类标准。
Am J Ophthalmol. 2021 Aug;228:205-211. doi: 10.1016/j.ajo.2021.03.036. Epub 2021 Apr 9.
10
Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease.Vogt-小柳-原田病视网膜下纤维化的纵向观察
BMC Ophthalmol. 2018 Jan 15;18(1):6. doi: 10.1186/s12886-018-0670-0.